guidelines:
  1: UCSF_CAPRA_prostate_cancer_risk.v1
test_cases:
- id: case_1:Age<50, total score = 0
  input:
    1:
      gt0008|Birthdate: 1989-06-02T07:43Z
      gt0012|PSA value at diagnosis: 5,ng/mL
      gt0014|Primary: 0|local::at0010|N/A|
      gt0015|Secondary: 0|local::at0016|N/A|
      gt0017|T stage: 1|local::at0005|T1c|
      gt0022|Percent biopsy cores positive for cancer: 0|local::at0005|< 34%|
  expected_output:
    1:
      gt0010|Age: 30,a
      gt0024|Percent biopsy cores positive for cancer: 0|local::at0005|< 34%|
      gt0027|Gleason pattern score: 0|local::at0021|No 4 or 5 pattern present|
      gt0026|PSA at diagnosis score: 0|local::at0016|< 6|
      gt0029|Total score: 0
      gt0028|Prostate T staging score: 0|local::at0024|T1 or T2|
      gt0025|Age score: 0|local::at0014|< 50 years|
      'gt0059|Score interpretation: 10 Year Overall survival % likelihood': 0|local::at0035|71.4%|
      'gt0055|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood': 0|local::at0029|99.7%|
      gt0060|Managment: 0|local::at0011|Consider routine surveillance.|
      'gt0054|Score interpretation: 5 Year Metastasis-free interval % likelihood': 0|local::at0021|99.3%|
      'gt0056|Score interpretation: 5 Year Overall survival % likelihood': 0|local::at0041|92.5%|
      'gt0058|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood': 0|local::at0038|97.1%|
      'gt0057|Score interpretation: 10 Year Metastasis-free interval % likelihood': 0|local::at0025|97.5%|
      gt0053|Risk level: 0|local::at0015|Very low risk|

- id: case_2:Age<50, total score = 2
  input:
    1:
      gt0008|Birthdate: 1989-06-02T07:43Z
      gt0012|PSA value at diagnosis: 6,ng/mL
      gt0014|Primary: 1|local::at0011|Closely resembles normal prostate|
      gt0015|Secondary: 1|local::at0017|Closely resembles normal prostate.|
      gt0017|T stage: 2|local::at0006|T2a|
      gt0022|Percent biopsy cores positive for cancer: 1|local::at0006|>= 34%|
  expected_output:
    1:
      gt0010|Age: 30,a
      gt0024|Percent biopsy cores positive for cancer: 1|local::at0006|>= 34%|
      gt0027|Gleason pattern score: 0|local::at0021|No 4 or 5 pattern present|
      gt0026|PSA at diagnosis score: 1|local::at0017|6  to 10|
      gt0029|Total score: 2
      gt0028|Prostate T staging score: 0|local::at0024|T1 or T2|
      gt0025|Age score: 0|local::at0014|< 50 years|
      'gt0059|Score interpretation: 10 Year Overall survival % likelihood': 0|local::at0035|71.4%|
      'gt0055|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood': 0|local::at0029|99.7%|
      gt0060|Managment: 1|local::at0012|Consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy)|
      'gt0054|Score interpretation: 5 Year Metastasis-free interval % likelihood': 0|local::at0021|99.3%|
      'gt0056|Score interpretation: 5 Year Overall survival % likelihood': 0|local::at0041|92.5%|
      'gt0058|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood': 0|local::at0038|97.1%|
      'gt0057|Score interpretation: 10 Year Metastasis-free interval % likelihood': 0|local::at0025|97.5%|
      gt0053|Risk level: 1|local::at0016|Low risk|

- id: case_3:Age <50, total score = 3
  input:
    1:
      gt0008|Birthdate: 1989-06-02T07:43Z
      gt0012|PSA value at diagnosis: 11,ng/mL
      gt0014|Primary: 2|local::at0012|Increased stroma with well-formed glands|
      gt0015|Secondary: 2|local::at0018|Increased stroma with well-formed glands|
      gt0017|T stage: 3|local::at0007|T2b|
      gt0022|Percent biopsy cores positive for cancer: 1|local::at0006|>= 34%|
  expected_output:
    1:
      gt0010|Age: 30,a
      gt0024|Percent biopsy cores positive for cancer: 1|local::at0006|>= 34%|
      gt0027|Gleason pattern score: 0|local::at0021|No 4 or 5 pattern present|
      gt0026|PSA at diagnosis score: 2|local::at0018|10 to 20|
      gt0029|Total score: 3
      gt0028|Prostate T staging score: 0|local::at0024|T1 or T2|
      gt0025|Age score: 0|local::at0014|< 50 years|
      'gt0059|Score interpretation: 10 Year Overall survival % likelihood': 1|local::at0036|59.7%|
      'gt0055|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood': 1|local::at0030|98.6%|
      gt0060|Managment: 1|local::at0012|Consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy)|
      'gt0054|Score interpretation: 5 Year Metastasis-free interval % likelihood': 1|local::at0022|96.9%|
      'gt0056|Score interpretation: 5 Year Overall survival % likelihood': 1|local::at0042|90.2%|
      'gt0058|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood': 1|local::at0039|91.6%|
      'gt0057|Score interpretation: 10 Year Metastasis-free interval % likelihood': 1|local::at0026|93.3%|
      gt0053|Risk level: 2|local::at0017|Intermediate risk|

- id: case_4:Age <50, total score = 4
  input:
    1:
      gt0008|Birthdate: 1989-06-02T07:43Z
      gt0012|PSA value at diagnosis: 21,ng/mL
      gt0014|Primary: 3|local::at0013|Recognizable glands, but cells are darker.|
      gt0015|Secondary: 3|local::at0019|Recognizable glands, but cells are darker.|
      gt0017|T stage: 4|local::at0008|T2c|
      gt0022|Percent biopsy cores positive for cancer: 1|local::at0006|>= 34%|
  expected_output:
    1:
      gt0010|Age: 30,a
      gt0024|Percent biopsy cores positive for cancer: 1|local::at0006|>= 34%|
      gt0027|Gleason pattern score: 0|local::at0021|No 4 or 5 pattern present|
      gt0026|PSA at diagnosis score: 3|local::at0019|20 to 30|
      gt0029|Total score: 4
      gt0028|Prostate T staging score: 0|local::at0024|T1 or T2|
      gt0025|Age score: 0|local::at0014|< 50 years|
      'gt0059|Score interpretation: 10 Year Overall survival % likelihood': 1|local::at0036|59.7%|
      'gt0055|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood': 1|local::at0030|98.6%|
      gt0060|Managment: 2|local::at0013|Consider multimodal therapy (surgery with radiation, or radiation therapy with hormonal therapy).|
      'gt0054|Score interpretation: 5 Year Metastasis-free interval % likelihood': 1|local::at0022|96.9%|
      'gt0056|Score interpretation: 5 Year Overall survival % likelihood': 1|local::at0042|90.2%|
      'gt0058|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood': 1|local::at0039|91.6%|
      'gt0057|Score interpretation: 10 Year Metastasis-free interval % likelihood': 1|local::at0026|93.3%|
      gt0053|Risk level: 2|local::at0017|Intermediate risk|


- id: case_5:Age <50, total score = 9
  input:
    1:
      gt0008|Birthdate: 1989-06-02T07:43Z
      gt0012|PSA value at diagnosis: 31,ng/mL
      gt0014|Primary: 4|local::at0014|Few recognizable glands.|
      gt0015|Secondary: 4|local::at0020|Few recognizable glands|
      gt0017|T stage: 5|local::at0009|T3|
      gt0022|Percent biopsy cores positive for cancer: 1|local::at0006|>= 34%|
  expected_output:
    1:
      gt0010|Age: 30,a
      gt0024|Percent biopsy cores positive for cancer: 1|local::at0006|>= 34%|
      gt0027|Gleason pattern score: 3|local::at0023|4 or 5 pattern in primary|
      gt0026|PSA at diagnosis score: 4|local::at0020|> 30|
      gt0029|Total score: 9
      gt0028|Prostate T staging score: 1|local::at0025|T3a|
      gt0025|Age score: 0|local::at0014|< 50 years|
      'gt0059|Score interpretation: 10 Year Overall survival % likelihood': 2|local::at0037|42.0%|
      'gt0055|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood': 2|local::at0031|93.4%|
      gt0060|Managment: 3|local::at0044|Consider either multimodal therapy OR hormonal therapy|
      'gt0054|Score interpretation: 5 Year Metastasis-free interval % likelihood': 2|local::at0023|90.4%|
      'gt0056|Score interpretation: 5 Year Overall survival % likelihood': 2|local::at0043|78.7%|
      'gt0058|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood': 2|local::at0040|79.1%|
      'gt0057|Score interpretation: 10 Year Metastasis-free interval % likelihood': 2|local::at0027|83.4%|
      gt0053|Risk level: 4|local::at0019|Very High risk|


- id: case_6:Age >50, total score = 10
  input:
    1:
      gt0008|Birthdate: 1958-06-04T07:43Z
      gt0012|PSA value at diagnosis: 31,ng/mL
      gt0014|Primary: 5|local::at0015|Few or no recognizable glands.|
      gt0015|Secondary: 5|local::at0021|Few or no recognizable glands.|
      gt0017|T stage: 5|local::at0009|T3|
      gt0022|Percent biopsy cores positive for cancer: 1|local::at0006|>= 34%|
  expected_output:
    1:
      gt0010|Age: 61,a
      gt0024|Percent biopsy cores positive for cancer: 1|local::at0006|>= 34%|
      gt0027|Gleason pattern score: 3|local::at0023|4 or 5 pattern in primary|
      gt0026|PSA at diagnosis score: 4|local::at0020|> 30|
      gt0029|Total score: 10
      gt0028|Prostate T staging score: 1|local::at0025|T3a|
      gt0025|Age score: 1|local::at0015|â‰¥ 50 years|
      'gt0059|Score interpretation: 10 Year Overall survival % likelihood': 2|local::at0037|42.0%|
      'gt0055|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood': 2|local::at0031|93.4%|
      gt0060|Managment: 3|local::at0044|Consider either multimodal therapy OR hormonal therapy|
      'gt0054|Score interpretation: 5 Year Metastasis-free interval % likelihood': 2|local::at0023|90.4%|
      'gt0056|Score interpretation: 5 Year Overall survival % likelihood': 2|local::at0043|78.7%|
      'gt0058|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood': 2|local::at0040|79.1%|
      'gt0057|Score interpretation: 10 Year Metastasis-free interval % likelihood': 2|local::at0027|83.4%|
      gt0053|Risk level: 4|local::at0019|Very High risk|
